Vujadinovic, M.

English

Replication-incompetent AdV vaccine vectors have a demonstrated ability to induce potent antigen-specific immune responses and an acceptable safety profile in humans. Several immunization schedules have currently been tested in clinical trials; single or multiple doses of an AdV based vaccine followed by a single or multiple dose of an alternative vector (e.g. AdV or MVA), a mixture of monovalent AdV vectors, or an AdV prime combined with (adjuvanted) protein/virus-like particle (VLP) boost. While these schedules have resulted in potent immunity with a favorable safety profile, they may be complex for general implementation after licensure. Advances in the design of AdV vector vaccines offer several alternatives: AdV vectors engineered to display an antigen on the outer capsid surface, functioning much like a VLP vaccine to induce B-cell antigen-specific immune responses. Unlike a typical VLP platform, AdV antigen-display vectors induce potent immune responses without the need for an adjuvant. Importantly, AdV antigen-display vectors can be designed to genetically encode specific antigens. The AdV genome can further be engineered to genetically encode more than one antigen resulting in a ‘multivalent’ vector. This thesis focuses on advancing the design of AdV vectors as vaccines against infectious diseases

International Migration, Integration and Social Cohesion online publications

Advances in the design of adenoviral vectored vaccines

https://pure.uva.nl/ws/files/44275082/Thesis.pdf

Advances in the design of adenoviral vectored vaccines

Abstract

Similar works

Full text

Available Versions

International Migration, Integration and Social Cohesion online publications